2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2519

Cenerimod, a Potent, Selective and Orally Active Sphingosine 1-phosphate Receptor 1 Modulator, Reduced Blood Antibody-secreting Cells in Patients with SLE
Abstract Number: 2520

Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 3 Cohorts of an Open-Label Phase 1b Dose Escalation Trial
Abstract Number: 2521

Rituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
Abstract Number: 2522

Frequency and Early Prediction of Hydroxychloroquine Induced Retinopathy in SLE
Abstract Number: 2523

Contemporary Prescription Opioid Use and Predictors Among Patients with Systemic Lupus Erythematosus
Abstract Number: 2524

24-Month Outcomes Associated with Belimumab in Black/African-American Patients with Systemic Lupus Erythematosus in a Clinical Practice Setting in the United States
Abstract Number: 2525

Within-Trial Cost Analysis of Flares from a Phase 3 Clinical Trial Evaluating Subcutaneous Belimumab for the Treatment of Systemic Lupus Erythematosus
Abstract Number: 2526

Antimalarial Agents Improve Physical Functioning in Patients with Systemic Lupus Erythematosus
Abstract Number: 2527

Cytokine and Autoantibody Profiles During Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
Abstract Number: 2528

Effect of Additional Administration of HCQ on Pro-inflammatory Cytokine Expression, Especially in Lupus Nephritis
Abstract Number: 2529

Safety of Chloroquine and Hydroxychloroquine During Pregnancy: A Systematic Review and Meta-Analysis
Abstract Number: 2530

Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome
Abstract Number: 2531

Low Vitamin D Is Associated with Miscarriage and Preterm Birth in SLE with a U-shaped Relationship
Abstract Number: 2532

Effect of Treatment on Antiphospholipid Antibodies in SLE
Abstract Number: 2533

Hydroxychloroquine Increases Low C3 in SLE

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].